Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

About this update from Allarity Therapeutics, Inc.

TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the United States Patent and Trademark Office (USPTO) has granted the key U.S. patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent has a term extending into April 2042. The patent grant follows the USPTO's Notice of Allowance for the stenoparib DRP® companion diagnostic formerly announced by Allarity in April 2026. "This is a critical step for Allarity. With this U.S. patent now granted and providing protection into 2042, we have established an important long-term intellectual property foundation for stenoparib and our DRP® companion diagnostic," said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. "Looking ahead, our goal is to use the stenoparib DRP® to help identify the patients most likely to benefit from treatment. This patent provides the foundation for advancing a more precise, patient-selection-driven approach to ovarian cancer and accelerating stenoparib toward FDA approval." The granted patent covers methods for predicting clinical benefit from stenoparib based on gene-expression profiles derived from tumor samples, as well as methods for selecting patients most likely to benefit from stenoparib treatment using the stenoparib DRP® test. The patent protects Allarity's long-term commercial strategy, allowing exclusivity for stenoparib when used in concert with the stenoparib DRP® companion diagnostic in the United States into April 2042. Allarity has also secured patent protection for the stenoparib DRP® in Europe and Australia into 2039, with related applications pending in several additional international markets. About Stenoparib/2X-121Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, especially drug-resistant cancers. By inhibiting PARP and bloc...

View stock analysis, news, and events for Allarity Therapeutics, Inc.